Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) announced a Next Day Disclosure Return for changes in its issued H Shares. As of 14 January 2026, the company had 109,063,785 issued shares (excluding treasury shares) and 33,000 treasury shares, totaling 109,096,785 issued shares.
On 19 January 2026, the company repurchased 28,400 shares at a volume-weighted average price of HKD 8.895 per share, representing approximately 0.02604% of the then issued shares. The closing balance on 19 January 2026 shows 109,035,385 issued shares (excluding treasury shares) and 61,400 treasury shares, maintaining the total number of issued shares at 109,096,785.
The announcement also notes that 28,400 shares were repurchased on the Hong Kong Stock Exchange at prices ranging between HKD 8.89 and HKD 8.9 per share, with the aggregate payment of HKD 252,618. None of the repurchased shares were cancelled; they are held as treasury shares.
Under the repurchase mandate approved on 11 June 2025, the company is authorized to repurchase up to 10,909,678 shares. Since then, 61,400 shares (0.05628% of the issued shares on the mandate date) have been repurchased. There is a moratorium period restricting any further issue of new shares or sale/transfer of treasury shares until 18 February 2026.
Comments